

Poly(hydrophobic amino acids) and liposomes for delivery of vaccine against Group A Streptococcus

Armira Azuar¹, Harrison Y. R. Madge¹, Jennifer C. Boer², Jazmina G. Cruz³, Jingwen Wang¹, Zeinab G. Khalil⁴, Cyril Deceneux², Georgia Goodchild², Jieru Yang¹, Prashamsa Koirala¹, Waleed M. Hussein¹, Robert J. Capon⁴, Magdalena Plebanski², Istvan Toth^{1,4,5*} and Mariusz Skwarczynski^{1,*}

¹ School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia

² School of Health and Biomedical Sciences, RMIT University, Bundoora West, VIC 3083, Australia

³ Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD 4102, Australia

⁴ Institute of Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia

⁵ School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia

* Correspondence: Email: i.toth@uq.edu.au; Tel: (617) 3346 9892 (I.T.) and Email: m.skwarczynski@uq.edu.au; Tel: (617) 3346 9894 (M.S.)

Supporting Information

Figure S1: Standard curve of compounds 1 and 2;

Figure S2: Immunization schedule;

Figure S3: Analysis of the purified compounds by analytical RP-HPLC and ESI-MS;

Figure S4: DLS spectra of particle size;

Figure S5: Liposome size stability;

Figure S6: Vaccine candidate stability in serum;

Figure S7: MTT cytotoxicity assays;

Figure S8: Dendritic cell uptake;




Figure S1. Standard curves of peptide **1** and polyleucine conjugate **2** used to calculate the concentrations of compound entrapped in the liposomes. These standard curves were plotted using area under compounds' peak against different compound concentrations (dissolved in PBS:methanol solution) that were injected (30 μ L) into analytical RP-HPLC (on C18 or C4 Vydac column for compounds **1** and **2**, respectively) using 0-100% gradient of solvent B for 30 min with compound detection at 214 nm.




Figure S2. Immunization schedule with marked immunization, serum, and saliva collection days.




Figure S3. Analysis of purified compounds **1** and **2** by analytical RP-HPLC and ESI-MS. The compounds were purified using preparative RP-HPLC with solvent B concentration gradient 30-50% (**1**) and 65-85% (**2**) from Rt 5 min to 30 min. Analytical RP-HPLC graphs show pure compounds in single peak. The mass from these peaks, matched to the desired compounds in ESI-MS. "X" marks the background noise of the RP-HPLC column.




Figure S4. DLS spectra of particle size, by intensity (top) and number (bottom) for compounds **1** and **2**, encapsulated liposomes **L1** and **L2**, and blank liposome.




Figure S5. Liposome size stability over 7 days period at RT.




Figure S6. Stability of the vaccine candidates after incubation in FBS at 37°C for 1 hour.




Figure S7. MTT cytotoxicity assay of polyleucine conjugate **2** and liposome **L2**.




Figure S8. Microscopy of dendritic cells showing nanoparticle **2** and liposome **L2** uptake. Confocal 60x in oil immersion showing nanoparticle and liposome uptake. Cell channels were split to (a) Dapi channel showing cell nuclei (blue staining), (b) Alx594 channel showing CD11c cytoplasm (red staining; CD11c membrane marker was chosen to show nanoparticle/liposome uptake, where particles are surrounded by red staining in the membrane), (c) FITC channel showing nanoparticle or liposome (green staining) and (d) merged images showing nanoparticles or liposomes were uptaken into the cells.